Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
NCT ID: NCT00894868
Last Updated: 2020-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
798 participants
INTERVENTIONAL
2009-05-31
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure
NCT03292653
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
NCT03521934
Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
NCT06435156
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
NCT03098979
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vildagliptin
vildagliptin
Placebo
placebo of vildagliptin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
vildagliptin
placebo of vildagliptin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CHF (NYHA Class I, Class II, or Class III) at Visit 1
* LVEF \< 40%
Exclusion Criteria
* FPG ≥ 270 mg/dL (≥15 mmol/L)
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Benešov, Czech Republic, Czechia
Novartis Investigative Site
Havířov, Czech Republic, Czechia
Novartis Investigative Site
Litomyšl, Czech Republic, Czechia
Novartis Investigative Site
Prague, Czech Republic, Czechia
Novartis Investigative Site
Prague, CZE, Czechia
Novartis Investigative Site
Broumov, , Czechia
Novartis Investigative Site
Pardubice, , Czechia
Novartis Investigative Site
Copenhagen NV, , Denmark
Novartis Investigative Site
Copenhagen S, , Denmark
Novartis Investigative Site
Frederiksberg, , Denmark
Novartis Investigative Site
Hellerup, , Denmark
Novartis Investigative Site
Roskilde, , Denmark
Novartis Investigative Site
Slagelse, , Denmark
Novartis Investigative Site
Pärnu, , Estonia
Novartis Investigative Site
Tallinn, , Estonia
Novartis Investigative Site
Tallinn, , Estonia
Novartis Investigative Site
Tartu, , Estonia
Novartis Investigative Site
Alsdorf, , Germany
Novartis Investigative Site
Bad Oeynhausen, , Germany
Novartis Investigative Site
Dresden, , Germany
Novartis Investigative Site
Fulda, , Germany
Novartis Investigative Site
Kamp-Lintfort, , Germany
Novartis Investigative Site
Saarlouis, , Germany
Novartis Investigative Site
Senden, , Germany
Novartis Investigative Site
Alexandroupoli, , Greece
Novartis Investigative Site
Chios, , Greece
Novartis Investigative Site
Thessaloniki, , Greece
Novartis Investigative Site
Guatemala City, , Guatemala
Novartis Investigative Site
Guatemala City, , Guatemala
Novartis Investigative Site
Secunderabad, Andhra Pradesh, India
Novartis Investigative Site
Visakhapatnam, Andhra Pradesh, India
Novartis Investigative Site
Ahmedabad, Gujarat, India
Novartis Investigative Site
Vadodara, Gujarat, India
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
Mangalore, Karnataka, India
Novartis Investigative Site
Trivandrum, Kerala, India
Novartis Investigative Site
Indore, Madhya Pradesh, India
Novartis Investigative Site
Nagpur, Maharashtra, India
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, India
Novartis Investigative Site
Ludhiana, Punjab, India
Novartis Investigative Site
Jaipur, Rajasthan, India
Novartis Investigative Site
Lucknow, Uttar Pradesh, India
Novartis Investigative Site
Bergamo, BG, Italy
Novartis Investigative Site
Florence, FI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Passirana Di Rho, MI, Italy
Novartis Investigative Site
Pavia, PV, Italy
Novartis Investigative Site
Mercato San Severino, SA, Italy
Novartis Investigative Site
Siena, SI, Italy
Novartis Investigative Site
Novara, , Italy
Novartis Investigative Site
Daugavpils, , Latvia
Novartis Investigative Site
Preiļi, , Latvia
Novartis Investigative Site
Alytus, , Lithuania
Novartis Investigative Site
Kaunas, , Lithuania
Novartis Investigative Site
Vilnius, , Lithuania
Novartis Investigative Site
Vilnius, , Lithuania
Novartis Investigative Site
Gdansk, , Poland
Novartis Investigative Site
Kłodzko, , Poland
Novartis Investigative Site
Warsaw, , Poland
Novartis Investigative Site
Wroclaw, , Poland
Novartis Investigative Site
Bucharest, District 2, Romania
Novartis Investigative Site
Craiova, Jud. Dolj, Romania
Novartis Investigative Site
Baia Mare, Maramureş, Romania
Novartis Investigative Site
Brasov, , Romania
Novartis Investigative Site
Kaliningrad, , Russia
Novartis Investigative Site
Kazan', , Russia
Novartis Investigative Site
Krasnodar, , Russia
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
N.Novgorod, , Russia
Novartis Investigative Site
Nizhny Novgorod, , Russia
Novartis Investigative Site
Penza, , Russia
Novartis Investigative Site
Petrozavodsk, , Russia
Novartis Investigative Site
Saint Petersburg, , Russia
Novartis Investigative Site
Saint Petersburg, , Russia
Novartis Investigative Site
Saint Petersburg, , Russia
Novartis Investigative Site
Saint Petersburg, , Russia
Novartis Investigative Site
Samara, , Russia
Novartis Investigative Site
Saratov, , Russia
Novartis Investigative Site
Saratov, , Russia
Novartis Investigative Site
Singapore, , Singapore
Novartis Investigative Site
Singapore, , Singapore
Novartis Investigative Site
Dunajská Streda, Slovak Republic, Slovakia
Novartis Investigative Site
Nitra, Slovak Republic, Slovakia
Novartis Investigative Site
Banská Bystrica, , Slovakia
Novartis Investigative Site
Komárno, , Slovakia
Novartis Investigative Site
Košice, , Slovakia
Novartis Investigative Site
Lučenec, , Slovakia
Novartis Investigative Site
Modava Nad Bodvou, , Slovakia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
McMurray JJV, Ponikowski P, Bolli GB, Lukashevich V, Kozlovski P, Kothny W, Lewsey JD, Krum H; VIVIDD Trial Committees and Investigators. Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial. JACC Heart Fail. 2018 Jan;6(1):8-17. doi: 10.1016/j.jchf.2017.08.004. Epub 2017 Oct 11.
Related Links
Access external resources that provide additional context or updates about the study.
Results for CLAF237A23118 from the Novartis Clinical Trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-005012-41
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CLAF237A23118
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.